There is growing evidence that GLP-1 receptor agonists (GLP-1 RAs) — drugs such as Semaglutide and Tirzepatide — may help slow progression or improve outcomes in some cancers, including metastatic cancers. But the evidence is still early and not yet definitive.Researchers are seeing several possible effects: ● reduced inflammation and oxidative stress ● improved insulin resistance and metabolic control ● weight reduction (important because obesity promotes some cancers) ● possible direct effects on tumor-cell signaling pathwaysSome recent studies reported: ● possible slowing of prostate cancer growth  ● improved outcomes in metastatic renal cell carcinoma patients receiving immunotherapy  ● lower mortality in some colorectal cancer populations using GLP-1 drugs  ● broader analyses suggesting reduced risk of several obesity-related cancers However, there are important cautions: ● Most evidence is observational or laboratory-based, not yet large ra

[zlim...@gmail.com]

There is growing evidence that GLP-1 receptor agonists (GLP-1 RAs) — drugs such as Semaglutide and Tirzepatide — may help slow progression or improve outcomes in some cancers, including metastatic cancers. But the evidence is still early and not yet definitive.
Researchers are seeing several possible effects:
● reduced inflammation and oxidative stress
● improved insulin resistance and metabolic control
● weight reduction (important because obesity promotes some cancers)
● possible direct effects on tumor-cell signaling pathways
Some recent studies reported:
● possible slowing of prostate cancer growth 
● improved outcomes in metastatic renal cell carcinoma patients receiving immunotherapy 
● lower mortality in some colorectal cancer populations using GLP-1 drugs 
● broader analyses suggesting reduced risk of several obesity-related cancers 
However, there are important cautions:
● Most evidence is observational or laboratory-based, not yet large randomized cancer trials.
● Benefits may differ by cancer type.
● Some cancers may respond differently because GLP-1 receptors are not equally expressed in all tumors.
● Scientists are still studying long-term safety and whether benefits come mainly from weight loss/metabolic improvement rather than direct anti-cancer action. 
So the statement “GLP-1 RA may reduce progression of metastatic cancer” is currently considered plausible and supported by emerging research, but not yet proven as a standard cancer treatment.
Interestingly, this connects with your long-standing interest in ROS (reactive oxygen species), inflammation, metabolism, and aging. Many researchers now think cancer progression, metabolic disease, and aging share overlapping pathways involving:
● chronic inflammation
● insulin/IGF signaling
● mitochondrial stress
● oxidative damage
GLP-1 drugs appear to influence several of those pathways simultaneously.

Sent from Yahoo Mail for iPhone